113 related articles for article (PubMed ID: 23796200)
1. Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15].
See WA
Urol Oncol; 2013 Jul; 31(5):716-7. PubMed ID: 23796200
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?
Mertens LS; Meijer RP; Kerst JM; Bergman AM; van Tinteren H; van Rhijn BW; Horenblas S
J Urol; 2012 Oct; 188(4):1108-13. PubMed ID: 22901581
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
[TBL] [Abstract][Full Text] [Related]
4. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
See WA
Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
[TBL] [Abstract][Full Text] [Related]
5. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
Einerhand SMH; Black AJ; Zargar H; Fairey AS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobson NE; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Kassouf W; Dall'Era MA; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Garcia JA; Stephenson AJ; Shah JB; Daneshmand S; Zargar-Shoshtari K; Spiess PE; van Rhijn BWG; Black PC; Mertens LS
World J Urol; 2022 Nov; 40(11):2707-2715. PubMed ID: 36169695
[TBL] [Abstract][Full Text] [Related]
6. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
Zargar-Shoshtari K; Zargar H; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
J Urol; 2016 Jan; 195(1):53-9. PubMed ID: 26205531
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer.
von Deimling M; Mertens LS; van Rhijn BWG; Lotan Y; Spiess PE; Daneshmand S; Black PC; Pallauf M; D'Andrea D; Moschini M; Soria F; Del Giudice F; Afferi L; Laukhtina E; Yanagisawa T; Kawada T; Teoh JY; Abufaraj M; Ploussard G; Roumiguié M; Karakiewicz PI; Babjuk M; Gontero P; Xylinas E; Rink M; Shariat SF; Pradere B
Eur Urol Open Sci; 2023 May; 51():39-46. PubMed ID: 37187719
[TBL] [Abstract][Full Text] [Related]
8. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
[TBL] [Abstract][Full Text] [Related]
9. Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function.
Sella A; Kovel S
Int Braz J Urol; 2012; 38(1):49-56. PubMed ID: 22397786
[TBL] [Abstract][Full Text] [Related]
10. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Miyake M; Shimizu T; Nishimura N; Kiba K; Maesaka F; Oda Y; Tachibana A; Tomizawa M; Ohmori C; Matsumura Y; Ichikawa K; Mizobuchi S; Yoshikawa T; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K;
Clin Genitourin Cancer; 2022 Apr; 20(2):196.e1-196.e9. PubMed ID: 34916166
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients.
Lucca I; Rouprêt M; Kluth L; Rink M; Tilki D; Fajkovic H; Kassouf W; Hofbauer SL; de Martino M; Karakiewicz PI; Briganti A; Trinh QD; Seitz C; Fritsche HM; Burger M; Lotan Y; Kramer G; Shariat SF; Klatte T
BJU Int; 2015 May; 115(5):722-7. PubMed ID: 24905084
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Huang J; Su R; Chen Z; Jiang S; Chen M; Yuan Y; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Li C; Wang Z; Bao Y; Cai M; Guo J; Wei Q; Xue W
Oncoimmunology; 2022; 11(1):2124691. PubMed ID: 36148322
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
14. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.
Sugimoto K; Taguchi S; Kishitani K; Kawai T; Masuda K; Nakamura Y; Kinjo M; Tambo M; Miyakawa J; Akiyama Y; Yamada Y; Sato Y; Yamada D; Nakagawa T; Fukuhara H; Kume H
BMC Urol; 2022 Nov; 22(1):177. PubMed ID: 36352389
[TBL] [Abstract][Full Text] [Related]
15. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
Shirotake S; Kikuchi E; Tanaka N; Matsumoto K; Miyazaki Y; Kobayashi H; Ide H; Obata J; Hoshino K; Kaneko G; Hagiwara M; Kosaka T; Kanao K; Kodaira K; Hara S; Oyama M; Momma T; Miyajima A; Nakagawa K; Hasegawa S; Nakajima Y; Oya M
J Urol; 2015 Apr; 193(4):1122-8. PubMed ID: 25444957
[TBL] [Abstract][Full Text] [Related]
16. Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Einerhand SMH; van Dijk N; van Dorp J; de Feijter JM; van Montfoort ML; van de Kamp MW; Schaake EE; Boellaard TN; Hendricksen K; van der Heijden MS; van Rhijn BWG
Int J Cancer; 2022 Dec; 151(11):2004-2011. PubMed ID: 35603905
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination.
Nichols RC; Sweetser MG; Mahmood SK; Malamud FC; Dunn NP; Adams JP; Kyker JS; Lydick K
Int J Cancer; 2000 Oct; 90(5):281-6. PubMed ID: 11091352
[TBL] [Abstract][Full Text] [Related]
18. Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
Minato A; Fujimoto N; Kubo T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1063-e1067. PubMed ID: 28803791
[TBL] [Abstract][Full Text] [Related]
19. Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study.
Richters A; Boormans JL; van der Heijden MS; van der Heijden AG; Meijer RP; Mehra N; Kiemeney LALM; Aben KKH
Eur Urol Focus; 2022 Jul; 8(4):995-1002. PubMed ID: 34535437
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer.
Afferi L; Lonati C; Montorsi F; Briganti A; Necchi A; Mari A; Minervini A; Campi R; di Trapani E; de Cobelli O; Karnes RJ; Ahmed M; Mir MC; Algarra MA; Rink M; Zamboni S; Simeone C; Krajewski W; Xylinas E; Soria F; Hendricksen K; Einerhand S; Mattei A; Carando R; Roumiguié M; Bajeot AS; Black PC; Shariat SF; Moschini M;
World J Urol; 2022 Jun; 40(6):1489-1496. PubMed ID: 35142865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
